Provided by Tiger Fintech (Singapore) Pte. Ltd.

Passage Bio, Inc.

0.3292
-0.0174-5.02%
Post-market: 0.33740.0082+2.49%17:07 EDT
Volume:101.06K
Turnover:35.00K
Market Cap:20.46M
PE:-0.31
High:0.3780
Open:0.3620
Low:0.3150
Close:0.3466
Loading ...

Passage Bio Inc expected to post a loss of 23 cents a share - Earnings Preview

Reuters
·
09 May

Major Stakeholder Makes a Big Move with Passage Bio Shares!

TIPRANKS
·
25 Apr

Major Shareholder Orbimed Advisors Makes a Bold Move with Passage Bio Stock!

TIPRANKS
·
18 Apr

Passage Bio (PASG) Upgraded to Buy: Here's What You Should Know

Zacks
·
08 Mar

Analysts Offer Insights on Healthcare Companies: Ventyx Biosciences (VTYX), Black Diamond Therapeutics (BDTX) and Passage Bio (PASG)

TIPRANKS
·
07 Mar

Chardan Cuts Price Target on Passage Bio to $6 From $7, Keeps Buy Rating

MT Newswires Live
·
05 Mar

U.S. RESEARCH ROUNDUP-Accolade, CrowdStrike, Marriott International

Reuters
·
05 Mar

Passage Bio Inc : Chardan Capital Markets Cuts Target Price to $6 From $7

THOMSON REUTERS
·
05 Mar

Passage Bio Is Maintained at Buy by Chardan Capital

Dow Jones
·
05 Mar

Passage Bio Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
05 Mar

Passage Bio Reports 2024 Financial Results and Program Advances

TIPRANKS
·
04 Mar

BRIEF-Passage Bio Reports Fourth Quarter and Full Year 2024 Results

Reuters
·
04 Mar

Passage Bio FY Income From Operations USD -70.4 Million

THOMSON REUTERS
·
04 Mar

Passage Bio Inc Q4 Shr View $-0.20 -- Lseg Ibes Data

THOMSON REUTERS
·
04 Mar

Passage Bio Inc - Net Loss $12.7 Million, or $0.20 per Basic and Diluted Share for Q4 2024

THOMSON REUTERS
·
04 Mar

Passage Bio Inc - Extended Cash Runway Into 1Q 2027

THOMSON REUTERS
·
04 Mar

Passage Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Highlights

GlobeNewswire
·
04 Mar

Passage Bio Inc expected to post a loss of 20 cents a share - Earnings Preview

Reuters
·
28 Feb

Passage Bio to Participate in Upcoming Investor Conferences

GlobeNewswire
·
26 Feb

Optimistic Outlook for Passage Bio: Buy Rating Justified by Promising Clinical Results and Extended Cash Runway

TIPRANKS
·
10 Jan